BioDelivery Sciences International, Inc. (NASDAQ:BDSI) and Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have entered into a licensing deal under which Collegium will gain exclusive rights for the development and marketing of Onsolis in the U.S.
Onsolis is approved for the management of breakthrough pain in cancer patients aged 18 years and above who have been on opioid therapy and are tolerant to opioid therapy for their underlying persistent cancer pain.
As per the terms of the agreement, the manufacturing, marketing, distribution and sales of Onsolis in the U.S. is to be looked after by Collegium.
Key Takeaways of the Agreement
Collegium will make an upfront payment of $2.5 million to BioDelivery. On the first commercial sale of Onsolis in the U.S., BioDelivery will get $4 million. Additionally, BioDelivery stands to receive up to $17 million on the achievement of performance and sales milestones as well as royalties in the upper-teens percent on various annual U.S. net sales thresholds.
We remind investors that Onsolis’ marketing was temporarily suspended in 2012 following discussions with the FDA regarding certain appearance-related issues raised by the agency during an inspection of Aveva’s manufacturing facility, the company’s North American manufacturing partner for Onsolis.
Collegium expects to re-launch the product in the U.S. by mid-2017. The licensing deal makes sense given Collegium’s focus in the pain management market following the recent approval of Xtampza ER.
Both BioDelivery and Collegium are Zacks Rank #3 (Hold) stocks. Some better-ranked stocks include ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) and Heska Corp. (NASDAQ:HSKA) -- both are Zacks Rank #1 (Strong Buy) stocks.
BIODELIVERY SCI (BDSI): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
COLLEGIUM PHARM (COLL): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
Original post
Zacks Investment Research